Chengdu Kanghong Pharma 
Welcome,         Profile    Billing    Logout  
 3 Products   3 Diseases   3 Products   28 Trials   310 News 


«123456789»
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  Long-Term Efficacy of Intravitreal Conbercept Injection in the Treatment of Idiopathic Choroidal Neovascularization. (Pubmed Central) -  Feb 9, 2021   
    This study provides an effective approach to separate the charge isomers of the heavily glycosylated protein drugs, and to quantitatively explore the site-specific N-glycans dynamics along with the different charge isomers. Intravitreal injection of conbercept shows favorable effectiveness in the treatment of idiopathic CNV during a long-term period of follow-up.
  • ||||||||||  Beovu (brolucizumab-dbll) / Novartis, faricimab (RG7716) / Roche, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  HIGHLIGHTS OF ADVANCES IN MEDICAL RETINA FROM THE VIRTUAL WORLD OPHTHALMOLOGY CONGRESS 2020. (Pubmed Central) -  Feb 3, 2021   
    Medical retina continues to be a rapidly advancing field within ophthalmology with new research findings having great implications for treatment burden and service delivery. This report summaries the highlights of advances within the medical retina subspecialty from free papers in WOC 2020.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity. (Pubmed Central) -  Dec 18, 2020   
    We observed that IVC 0.25 mg in ROP patients suppressed the circulating levels of VEGF-A and VEGF-D as of 1 week after injection, and these growth factor levels returned to baseline at 4 weeks. No significant differences were observed in the serum levels of the other cytokines between baseline and 1 or 4 weeks after IVC.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  Efficacy of conbercept combined with panretinal photocoagulation in the treatment of proliferative diabetic retinopathy. (Pubmed Central) -  Dec 16, 2020   
    Within-group analysis indicated a significant decrease in NV leakage at month 3 and month 6 in both groups, and a significant increase in BCVA at 1 month in the combination group. In summary, the combination of intravitreal injection of conbercept and PRP can significantly reduce the NV of PDR patients and achieve better BCVA during the drug's lifespan compared with PRP alone.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  Proteomic Study of Aqueous Humor and Its Application in the Treatment of Neovascular Glaucoma. (Pubmed Central) -  Nov 18, 2020   
    The present experiment provided a comprehensive AH proteome analysis and expanded the profile of human AH proteome. The differential AH proteomic analysis of NVG treatment indicated that AH proteome can reflect the pathophysiological changes in drug intervention.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Enrollment closed:  Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) (clinicaltrials.gov) -  Oct 19, 2020   
    P3,  N=1140, Active, not recruiting, 
    An intravitreal injection of conbercept after vitrectomy improved visual acuity and seemed to reduce the recurrence of VH resulting in prompt visual recovery in the PDR patients. Recruiting --> Active, not recruiting
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration. (Pubmed Central) -  Oct 4, 2020   
    The mean decrease of mPEDH and cPEDH at the last follow-up after switching was significantly larger in the IVR subgroup than in the IVB subgroup (p=0.023 and 0.010). Our results indicate that switching from intravitreal conbercept injections to bevacizumab or ranibizumab can lead to significant improvement of CMT, PED, and IRF and slight improvement of BCVA in a short period of time for persistent nAMD patients.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  The fellow eye effect of unilateral intravitreal conbercept injections in eyes with diabetic macular edema. (Pubmed Central) -  Sep 25, 2020   
    Our results indicate that switching from intravitreal conbercept injections to bevacizumab or ranibizumab can lead to significant improvement of CMT, PED, and IRF and slight improvement of BCVA in a short period of time for persistent nAMD patients. Intravitreal conbercept injection results in decreased CRT and increased BCVA in untreated eyes, which is consistent with the changes in treated eyes for patients with bilateral DME.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal, HEOR:  Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration. (Pubmed Central) -  Sep 23, 2020   
    The potential benefits of conbercept, aflibercept, and ranibizumab has been reported in patients with wet age-related macular degeneration (wAMD)...Probabilistic sensitivity analysis (PSA) indicated that IVT-CON yielded the greatest probabilities of cost-effectiveness (about 92%) compared with other strategies. Conbercept is a cost-effective option for the treatment of wAMD in a Chinese healthcare setting.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Review, Journal:  The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review. (Pubmed Central) -  Aug 30, 2020   
    However, there was a greater polyp regression rate in the conbercept group at 12 months. This systematic review indicates that conbercept may achieve similar BCVA and CRT improvements as ranibizumab and aflibercept, with a superior rate of polyp regression at 12 months.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  An update on conbercept to treat wet age-related macular degeneration. (Pubmed Central) -  Aug 20, 2020   
    In this regard, the phase III PHOENIX trial has reported a good clinical efficacy and safety profile of conbercept for w-AMD, also by adopting a quarterly regimen. In this review, we will discuss its pharmacokinetics, pharmacodynamics, clinical efficacy, without neglecting also its safety and tolerability profile.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Preclinical, Journal:  Effects of VEGF Inhibitor Conbercept on Corneal Neovascularization Following Penetrating Keratoplasty in Rabbit Model. (Pubmed Central) -  Aug 18, 2020   
    There were no significant differences with the expression of keratocan in all groups except that it significantly declined at the 4th week as to the second week in all groups and P values were 0.022, 0.020 and 0.014 in control (C), topical (E1), and subconjunctival (E2) group, respectively. The study found that conbercept inhibited the formation of corneal neovascularization without affecting keratocan-mediated corneal wound healing and there were no significant differences between topical administration of different doses of conbercept on the rabbit corneal neovascularization after penetrating keratoplasty in this study.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  Vitreous Proteomics Provides New Insights into Antivascular Endothelial Growth Factor Therapy for Pathologic Myopia Choroid Neovascularization. (Pubmed Central) -  Aug 12, 2020   
    Seven PMRS patients were enrolled: 3 PMRS patients as control group, 3 PMRS patients with coexisting choroidal neovascularization (CNV) who developed retinoschisis aggravation after multiple intravitreal conbercept (IVC) injections, and one PMRS patient with coexisting CNV without leakage CNV (CNV-)...These suggest that multiple IVC injections may increase the VH αSMA concentration, which may contribute to posterior hyaloid membrane or retinal inner limiting membrane contraction. Label-free proteomics is an efficient method to provide further insight into the pathogenesis of vitreoretinal diseases.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Journal:  SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. (Pubmed Central) -  Jul 2, 2020   
    No significant difference was found in the visual acuity improvement of the patients with PCV between the conbercept group and ranibizumab group at 6 months. However, conbercept was superior to ranibizumab monotherapy in the regression of polyps.